Robert Andtbacka Discusses T-VEC Trials
Robert Andtbacka, MD, associate professor, Division of Surgical Oncology Department of Surgery, University of Utah School of Medicine, discusses past, present, and future trials for T-VEC.
Robert Andtbacka, MD, associate professor, Division of Surgical Oncology Department of Surgery, University of Utah School of Medicine, discusses past, present, and future trials investigating T-VEC in melanoma.
T-VEC was already approved as a monotherapy, but is currently in ongoing studies to be used as a combination therapy. A phase I study showed that the therapy did not increase toxicity when combined with ipilimumab, and response rate when combining the drugs was high. Another study combined pembrolizumab with T-VEC and also showed no added toxicity and a 56% response rate.
An upcoming phase III study will compare the results of pembrolizumab plus T-VEC with pembrolizumab plus an injectable suspension.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
